Devonian Health Group Inc(GSD-X)
TSX Venture

Today's Change
Delayed Last Update
Day Low10.000
Day High10.000
Open:10.000
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Newswire.ca
Devonian Reports Results of its Annual General and Special Meeting of Shareholders
Newswire.ca
Devonian Health Group Inc. Reports Financial and Operating Results of its Three and Six Months Ended January 31, 2026
Newswire.ca
Devonian Reports Human Liver-on-a-Chip Data Demonstrating Disease-Relevant Modulation of MASH by Thykamine™, with Dose-Dependent Anti-Fibrotic and Anti-Inflammatory Effects
Newswire.ca
Devonian Advances Thykamine™ Patent Strategy with Proprietary Fingerprint and Robust Manufacturing Controls
Newswire.ca
Devonian reports additional molecular data from MASH liver study
Newswire.ca
DEVONIAN REPORTS POSITIVE RESULTS IN PULMONARY FIBROSIS STUDY
Newswire.ca
DEVONIAN APPOINTS DENNIS TURPIN AS CHIEF FINANCIAL OFFICER AND PROVIDES UPDATES ON STOCK OPTIONS GRANT
Newsfile
Upcoming Meeting Dates - January 26, 2026
Newswire.ca
DEVONIAN ANNOUNCES SHARE CONSOLIDATION IN FURTHER PREPARATION FOR POTENTIAL U.S. LISTING
Newswire.ca
Devonian Health Group Announces Grant of Stock Options
Newswire.ca
Devonian Health Group Reports Financial Results of its First Quarter Ended on October 31, 2025 and Provides Corporate Update
Newswire.ca
Devonian Health Group Announces Publication of Landmark Study Highlighting Thykamine™ as a Promising New Anti-Inflammatory Agent
Newswire.ca
Devonian Health Group Reports its Fourth Quarter and Annual 2025 Financial Results and Appointment of a New Board Member
Newswire.ca
Devonian Health Group Inc. announces its participation to the ThinkEquity Conference in New York and closing of a Non-Brokered Private Placement of Units
Business Wire
Devonian Provides Corporate Update and Additional Information Regarding its Previously Announced Private Placement
AI-generated - The Globe and Mail
Devonian Health Gr: Top 10 Undervalued Biotechnology Industry Stocks (GSD)
Business Wire
Devonian Health Group Reports Third Quarter 2025 Financial Results
AI-generated - The Globe and Mail
Devonian Health Gr: Top 10 Undervalued Biotechnology Industry Stocks (GSD)
Business Wire
Devonian Appoints New Officers and Announces Grant of Stock Options

Profile

Devonian Health Group Inc is operating in the pharmaceutical sector. It is engaged in the development and distribution of botanical drugs. The group is also involved in the development of value-added products for dermo-cosmetics. It has established a research effort focused on the anticipation of new solutions in the medical sector as well as in the cosmetic sector. The company's technology platform, The Supra Molecular Complex Extraction and Stabilization Technology provides a process of extraction, purification, stabilization, and conditioning of molecular complexes, as active botanical ingredients, from plants and algae. Its product portfolio includes pharmaceuticals like Thykamine, Pantoprazole, and Cleo-35; and cosmeceutical products like R-Spinasome and Purgenesis.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.